EcoDrugPlus

Topoisomerase (Dna) Ii Beta

Ensembl ID : ENSMSIG00000014921
Gene Symbol: TOP2B
1 Cross references
223 Possible Orthologues:

Trace Amine-Associated Receptor 1

Ensembl ID : ENSMSIG00000013404
Gene Symbol: TAAR1
1 Cross references
617 Possible Orthologues:

Transformed Mouse 3t3 Cell Double Minute 2

Ensembl ID : ENSMSIG00000022359
Gene Symbol: MDM2
1 Cross references
269 Possible Orthologues:

Transforming Growth Factor, Beta Receptor I

Ensembl ID : ENSMSIG00000021538
Gene Symbol: TGFBR1
1 Cross references
245 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1

Ensembl ID : ENSMSIG00000008184
Gene Symbol: TRPA1
1 Cross references
241 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily M, Member 8

Ensembl ID : ENSMSIG00000026361
Gene Symbol: TRPM8
1 Cross references
173 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily V, Member 1

Ensembl ID : ENSMSIG00000011817
Gene Symbol: TRPV1
1 Cross references
149 Possible Orthologues:

Translocator Protein

Ensembl ID : ENSMSIG00000017574
Gene Symbol: TSPO
1 Cross references
141 Possible Orthologues:

Transthyretin

Ensembl ID : ENSMSIG00000023575
Gene Symbol: TTR
1 Cross references
178 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSMSIG00000027705
Gene Symbol: TPH1
1 Cross references
270 Possible Orthologues:

Tubulin, Alpha 1a

Ensembl ID : ENSMSIG00000002382
Gene Symbol: TUBA1A
1 Cross references
140 Possible Orthologues:

Tubulin, Alpha 1c

Ensembl ID : ENSMSIG00000002410
Gene Symbol: TUBA1C
1 Cross references
120 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).